These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24786143)

  • 1. The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome.
    Sarma A; Cannon CP; de Lemos J; Rouleau JL; Lewis EF; Guo J; Mega JL; Sabatine MS; O'Donoghue ML
    J Am Heart Assoc; 2014 May; 3(3):e000784. PubMed ID: 24786143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
    Wiviott SD; de Lemos JA; Cannon CP; Blazing M; Murphy SA; McCabe CH; Califf R; Braunwald E
    Circulation; 2006 Mar; 113(11):1406-14. PubMed ID: 16534008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
    Dormuth CR; Hemmelgarn BR; Paterson JM; James MT; Teare GF; Raymond CB; Lafrance JP; Levy A; Garg AX; Ernst P;
    BMJ; 2013 Mar; 346():f880. PubMed ID: 23511950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
    Zhao SP; Yu BL; Peng DQ; Huo Y
    Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
    Bangalore S; Fayyad R; Hovingh GK; Laskey R; Vogt L; DeMicco DA; Waters DD;
    Am J Cardiol; 2014 Jun; 113(12):2018-20. PubMed ID: 24793673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
    Truong QA; Murphy SA; McCabe CH; Armani A; Cannon CP;
    Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):328-36. PubMed ID: 21487089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; McCabe CH; Cairns R; Tonkin AM; Sacks FM; Jackson G; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1405-10. PubMed ID: 16226162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
    Kang S; Liu Y; Liu XB
    Clin Ther; 2013 Aug; 35(8):1125-36. PubMed ID: 23932462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
    Brilakis ES; de Lemos JA; Cannon CP; Wiviott SD; Murphy SA; Morrow DA; Sabatine MS; Banerjee S; Blazing MA; Califf RM; Braunwald E
    Am J Cardiol; 2008 Sep; 102(5):552-8. PubMed ID: 18721511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
    Saw J; Brennan DM; Steinhubl SR; Bhatt DL; Mak KH; Fox K; Topol EJ;
    J Am Coll Cardiol; 2007 Jul; 50(4):291-5. PubMed ID: 17659194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
    Hilleman DE; Wurdeman RL; Lenz TL
    Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of incident diabetes among patients treated with statins: population based study.
    Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
    BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
    Austin PC; Mamdani MM
    Circulation; 2005 Aug; 112(9):1296-300. PubMed ID: 16116054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
    N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes.
    Colivicchi F; Tubaro M; Santini M
    Int J Cardiol; 2011 Oct; 152(1):56-60. PubMed ID: 20674999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.